Impact of anemia in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention
Analysis from the controlled abciximab and device investigation to lower late angioplasty complications (cadillac) trial
Eugenia Nikolsky, MD, PhD*, ,
Eve D. Aymong, MD, FACC*, ,
Amir Halkin, MD*, ,
Cindy L. Grines, MD, FACC ,
David A. Cox, MD, FACC ,
Eulogio Garcia, MD||,
Roxana Mehran, MD, FACC*, ,
James E. Tcheng, MD, FACC¶,
John J. Griffin, MD, FACC#,
Giulio Guagliumi, MD**,
Thomas Stuckey, MD, FACC ,
Mark Turco, MD, FACC ,
David A. Cohen, MD, FACC ,
Manuela Negoita, MD*, ,
Alexandra J. Lansky, MD, FACC*, and
Gregg W. Stone, MD, FACC*, ,*
* Cardiovascular Research Foundation, New York, New YorkUSA
Lenox Hill Heart and Vascular Institute, New York, New YorkUSA
William Beaumont Hospital, Royal Oak, MichiganUSA
Mid Carolina Cardiology, Charlotte, North CarolinaUSA
|| Hospital Gregorio Maranon, Madrid, Spain
¶ Duke Clinical Research Institute, Durham, North CarolinaUSA
# Virginia Beach General Hospital, Virginia Beach, VirginiaUSA
** Ospedali Riuniti di Bergamo, Bergamo, Italy
 Moses Cone Memorial Hospital, Greensboro, North CarolinaUSA
 Washington Adventist Hospital, Tacoma Park, MarylandUSA
 Beth Israel Hospital, Boston, MassachusettsUSA

View larger version (15K):
[in a new window]
|
Figure 1 Cumulative risk of death in patients with versus without anemia.
|
|

View larger version (18K):
[in a new window]
|
Figure 2 Rates of survival (A) and disabling stroke (B) at 1 year in patients undergoing percutaneous coronary intervention for acute myocardial infarction stratified by baseline anemia and gender. Open bars = 30 days; solid bars = 1 year.
|
|
|